PimobendanSelective PDE3 inhibitor.Ca2+ channel sensitizer CAS# 74150-27-9 |
- GSK256066 2,2,2-trifluoroacetic acid
Catalog No.:BCC1605
CAS No.:1415560-64-3
- Nortadalafil
Catalog No.:BCC1806
CAS No.:171596-36-4
- Bay 60-7550
Catalog No.:BCC1405
CAS No.:439083-90-6
- Oglemilast
Catalog No.:BCC1817
CAS No.:778576-62-8
- AN-2728
Catalog No.:BCC1361
CAS No.:906673-24-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 74150-27-9 | SDF | Download SDF |
| PubChem ID | 4823 | Appearance | Powder |
| Formula | C19H18N4O2 | M.Wt | 334.37 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 50 mg/mL (149.53 mM; Need ultrasonic) | ||
| Chemical Name | 3-[2-(4-methoxyphenyl)-3H-benzimidazol-5-yl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one | ||
| SMILES | CC1CC(=O)NN=C1C2=CC3=C(C=C2)N=C(N3)C4=CC=C(C=C4)OC | ||
| Standard InChIKey | GLBJJMFZWDBELO-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Pimobendan Dilution Calculator
Pimobendan Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.9907 mL | 14.9535 mL | 29.907 mL | 59.814 mL | 74.7675 mL |
| 5 mM | 0.5981 mL | 2.9907 mL | 5.9814 mL | 11.9628 mL | 14.9535 mL |
| 10 mM | 0.2991 mL | 1.4953 mL | 2.9907 mL | 5.9814 mL | 7.4767 mL |
| 50 mM | 0.0598 mL | 0.2991 mL | 0.5981 mL | 1.1963 mL | 1.4953 mL |
| 100 mM | 0.0299 mL | 0.1495 mL | 0.2991 mL | 0.5981 mL | 0.7477 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Pimobendan is a selective inhibitor of PDE3 with IC50 of 0.32 μM.
- Bisdethiobis(methylthio)gliotoxin
Catalog No.:BCN7351
CAS No.:74149-38-5
- DSC
Catalog No.:BCC2800
CAS No.:74124-79-1
- Norjuziphine
Catalog No.:BCN3367
CAS No.:74119-87-2
- SKF 83822 hydrobromide
Catalog No.:BCC7252
CAS No.:74115-10-9
- Ketorolac tromethamine salt
Catalog No.:BCC4431
CAS No.:74103-07-4
- Ketorolac
Catalog No.:BCC5190
CAS No.:74103-06-3
- ACV 1
Catalog No.:BCC5989
CAS No.:740980-24-9
- Cudratricusxanthone A
Catalog No.:BCN7649
CAS No.:740810-42-8
- Macamide B
Catalog No.:BCN1366
CAS No.:74058-71-2
- Ketanserin
Catalog No.:BCC5050
CAS No.:74050-98-9
- Lancifolin C
Catalog No.:BCN2019
CAS No.:74048-71-8
- Enoxacin (Penetrex)
Catalog No.:BCC3775
CAS No.:74011-58-8
- 2,3-Dehydrokievitone
Catalog No.:BCN4294
CAS No.:74161-25-4
- R547
Catalog No.:BCC3927
CAS No.:741713-40-6
- Haginin A
Catalog No.:BCN6861
CAS No.:74174-29-1
- Cyclokievitone
Catalog No.:BCC8159
CAS No.:74175-82-9
- Doxazosin
Catalog No.:BCC4218
CAS No.:74191-85-8
- Uplandicine
Catalog No.:BCN2055
CAS No.:74202-10-1
- 3-Bromo-7-nitroindazole
Catalog No.:BCC6770
CAS No.:74209-34-0
- Vintafolide
Catalog No.:BCC5265
CAS No.:742092-03-1
- Carbenoxolone disodium
Catalog No.:BCC3745
CAS No.:7421-40-1
- OSU-03012 (AR-12)
Catalog No.:BCC1255
CAS No.:742112-33-0
- Doronenine
Catalog No.:BCN2066
CAS No.:74217-57-5
- Baogongteng A
Catalog No.:BCN1874
CAS No.:74239-84-2
Pimobendan in Chronic Right Heart Failure in a Left Ventricular Assist Device Patient.[Pubmed:28018821]
Thorac Cardiovasc Surg Rep. 2016 Dec;5(1):39-40.
We report the case of a 76-year-old patient who developed chronic right heart failure 1 year after left ventricular assist device implantation due to ischemic cardiomyopathy. Initial recompensation was achieved through dobutamin, sildenafil, and levosimendan treatment. Yet, discharge was successful only after the off-label use of the oral calcium sensitizer Pimobendan. Ten months after discharge, the patient presents with no clinical signs of right heart failure and significantly improved right heart function without any impairment in quality of life.
Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure.[Pubmed:27644192]
J Vet Med Sci. 2017 Jan 20;79(1):29-34.
The aim of this study was to evaluate the efficacy of Pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD). Records of 197 client-owned dogs from 14 veterinary hospitals were included in this study. Dogs were administered conventional treatments with or without Pimobendan. Sixty-four dogs received a standard dose of Pimobendan (0.20-0.48 mg/kg every 12 hr (q12hr)), 49 dogs received a low dose of Pimobendan (0.05-0.19 mg/kg q12hr), and 84 dogs received conventional therapy alone. Dogs in the standard-dose and low-dose Pimobendan groups had significantly longer median survival times than dogs in the conventional group (334, 277 and 136 days, respectively; P<0.001). The reoccurrence rate of pulmonary edema in the standard-dose group was significantly lower than in the low-dose and conventional groups (43%, 59% and 62%, respectively; P<0.05). Combination of Pimobendan with a conventional treatment regimen significantly prolonged survival time after an initial episode of pulmonary edema in dogs with CHF caused by MMVD. There was no difference in survival between dogs administered standard and low doses of Pimobendan, but Pimobendan did prevent the reoccurrence of pulmonary edema in a dose-dependent manner.
Single-dose pharmacokinetics and cardiovascular effects of oral pimobendan in healthy cats.[Pubmed:27613648]
J Vet Cardiol. 2016 Dec;18(4):310-325.
INTRODUCTION: To investigate the pharmacokinetics and pharmacodynamics of oral Pimobendan in conscious, healthy cats. ANIMALS: Eight healthy adult cats. MATERIALS AND METHODS: A randomised, single-blinded, crossover design was used. Two oral doses of Pimobendan (0.625-mg [LD], 1.25-mg [HD]) and a control substance (3-mL water) were administered to each cat. Blood collection, echocardiography, and oscillometric blood pressure measurements were performed repeatedly for 12 h following each dose. Plasma concentrations of Pimobendan and the active metabolite, O-desmethylPimobendan (ODMP), were quantified using ultra-high-performance liquid chromatography tandem mass spectrometry. Cardiovascular parameters were evaluated for between- and within-treatment effects over time using linear mixed modelling. RESULTS: Pimobendan was rapidly absorbed and converted to ODMP with the Pimobendan AUC0-infinity greater than ODMP AUC0-infinity (ODMP:Pimobendan AUC0-infinity ratio 0.6 [LD] and 0.5 [HD]) despite a longer elimination half-life of ODMP (Pimobendan t1/2 0.8 h vs. ODMP t1/2 1.6 h [LD]; Pimobendan t1/2 0.7 h vs. ODMP t1/2 1.3 h [HD]). Averaged across all time points, Pimobendan increased several measures of systolic function; however, its effect could not be further characterised. Although treatment was well-tolerated, two cats vomited following HD and another had a ventricular premature beat recorded following LD. CONCLUSIONS: The lower ODMP:Pimobendan AUC0-infinity ratio compared to that observed previously in dogs suggests reduced metabolism in cats. Treatment effects were observed in measures of systolic function; however, the duration of action and differences in effects between the two Pimobendan doses could not be characterised. Further studies are required to evaluate Pimobendan in feline cardiovascular medicine.
Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.[Pubmed:27678080]
J Vet Intern Med. 2016 Nov;30(6):1765-1779.
BACKGROUND: Pimobendan is effective in treatment of dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD). Its effect on dogs before the onset of CHF is unknown. HYPOTHESIS/OBJECTIVES: Administration of Pimobendan (0.4-0.6 mg/kg/d in divided doses) to dogs with increased heart size secondary to preclinical MMVD, not receiving other cardiovascular medications, will delay the onset of signs of CHF, cardiac-related death, or euthanasia. ANIMALS: 360 client-owned dogs with MMVD with left atrial-to-aortic ratio >/=1.6, normalized left ventricular internal diameter in diastole >/=1.7, and vertebral heart sum >10.5. METHODS: Prospective, randomized, placebo-controlled, blinded, multicenter clinical trial. Primary outcome variable was time to a composite of the onset of CHF, cardiac-related death, or euthanasia. RESULTS: Median time to primary endpoint was 1228 days (95% CI: 856-NA) in the Pimobendan group and 766 days (95% CI: 667-875) in the placebo group (P = .0038). Hazard ratio for the Pimobendan group was 0.64 (95% CI: 0.47-0.87) compared with the placebo group. The benefit persisted after adjustment for other variables. Adverse events were not different between treatment groups. Dogs in the Pimobendan group lived longer (median survival time was 1059 days (95% CI: 952-NA) in the Pimobendan group and 902 days (95% CI: 747-1061) in the placebo group) (P = .012). CONCLUSIONS AND CLINICAL IMPORTANCE: Administration of Pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated. Prolongation of preclinical period by approximately 15 months represents substantial clinical benefit.
